logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

DoubleLine Capital: Large-scale borrowing and weak demand will continue to exert pressure; remains bearish on long-term U.S. Treasuries.

date
23/10/2026
Zhitong Finance APP has learned that Jeff Sherman, Deputy Chief Investment Officer of DoubleLine Capital, stated that he remains bearish on long-term U.S. Treasuries and believes that large-scale government borrowing and weak demand will continue to put pressure on the U.S. Treasury market.
Latest
1 m ago
Gilead Sciences (GILD.US) to acquire PepStar oral inflammatory drug program for $1.275 billion in cash, bolstering inflammatory bowel disease pipeline
4 m ago
Bojie Pharmaceutical (300404.SZ) private placement application accepted by Shenzhen Stock Exchange
7 m ago
Black Sesame Technologies (02533.HK) plans to cancel 1.98 million treasury shares to further enhance shareholder value.
8 m ago
Dano Medical-B (06872): Rifaquone (TNP-2092) Administered via Intra-articular Injection for the Treatment of Prosthetic Joint Infection Completes First Patient Enrollment in Multicenter Phase IIb Clinical Trial
12 m ago
CSPC Pharmaceutical Group (01093.HK): Batoclimab Injection (subcutaneous injection) has obtained a drug registration certificate issued by the National Medical Products Administration.
See all latestmore
logo
Contact US
qr
+852 - 60190728
[email protected]
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.